

Supplementary Information

The Winding Road of the Uvaretin Class of Natural Products: From Total Synthesis to Bioactive Agent Discovery.

Johnathan Dallman[‡], Ashabha Lansakara[‡], Thi Nguyen[‡], Chamitha Weeramange,
Wasundara Hulangamuwa, and Ryan J. Rafferty

Department of Chemistry, Kansas State University, 1212 Mid-Campus Drive North, Manhattan,
KS 66506

[‡]These authors contributed equally to the work



















Table of Contents




Friedel-Craft Alkylation Conditions	S2
Summary Table of all Bioactive Compounds: Sole Agents	S3
NMR Data for Synthesized Compounds	S4-23




Table S1: Attempting Conditions




Entry	Lewis acid	Conditions	Yields 15/16%
1		14 & Chalcone Compound to dioxane, add L.A. in dioxane in four portions 10 min apart at RT	0%, 62%
2		Chalcone Compound in dioxane, add L.A and heat at 60 °C, dropwise addition of 14 in dioxane over 2.5 h	23%, 46%
3		Chalcone Compound in dioxane heated to 60 °C, dropwise addition of 14 & L.A. in dioxane over 2.5 h	0%, 73%
4		<i>Same as entry 1</i> , except stirred for 12 h, then heated to 60 °C, 14 dissolved in dioxane with L.A. in two portions 45 min apart, stirred for 12 h, and then refluxed for 48 h	0%, 68%
<hr/>			
6		14 and Chalcone Compound in CH ₂ Cl ₂ , L.A. added, stirred at RT for 8 h, then refluxed for 24 h	0%, 0%
7		14 and Chalcone Compound in dioxane, L.A. added, heated at 60 °C for 48 h	31%, 0%
8		14 and L.A. in dioxane, heated at 60 °C, Chalcone Compound in dioxane added dropwise over 18 h	0%, 0%




Table S2: Summary of all sole bioactive agents.




						
9	10	22	24	27	29	
HeLa	>20	3.1 ± 1.0	18.7 ± 3.1	14.0 ± 1.0	>20	11.5 ± 1.1
A549	>20	9.8 ± 1.3	>20	16.9 ± 1.6	>20	8.4 ± 1.3
MIA PaCa-2	>20	14.3 ± 1.0	>20	>20	6.1 ± 1.6	11.8 ± 2.6
HCT-116	>20	>20	>20	>20	>20	>20
						
11	21	25	28			
HeLa	5.2 ± 1.4	>20	4.8 ± 0.6	12.2 ± 0.9		
A549	4.3 ± 0.9	19.7 ± 2.2	3.5 ± 0.8	>20		
MIA PaCa-2	14.3 ± 1.0	18.2 ± 1.7	5.6 ± 0.7	>20		
HCT-116	>20	>20	>20	>20		
						
30	31					
HeLa	9.7 ± 1.3	19.7 ± 0.6				
A549	4.2 ± 1.9	>20				
MIA PaCa-2	2.2 ± 0.6	7.8 ± 0.4				
HCT-116	>20	>20				
						
15	19	20				
HeLa	5.8 ± 0.5	2.7 ± 0.6	>20			
A549	8.5 ± 0.6	9.3 ± 1.1	>20			
MIA PaCa-2	9.4 ± 1.3	4.1 ± 0.3	>20			
HCT-116	>20	18.6 ± 2.5	>20			
						
26	2	Uvaretin (1)				
HeLa	3.1 ± 0.5	4.6 ± 1.4	3.7 ± 0.8			
A549	5.8 ± 1.8	4.3 ± 2.1	2.2 ± 1.0			
MIA PaCa-2	>20	5.1 ± 1.8	2.0 ± 1.1			
HCT-116	>20	19.5 ± 3.1	>20			


















































































CDCl₃



Uvaretin (1)

